A $1.4 million investment to upgrade Quotient Sciences’ facility in Boothwyn, Pa. (Chelsea Parkway) was recently completed, making critical updates to the facility while also refreshing many of the facility’s cGMP manufacturing spaces and transforming previously underutilized areas into fully operational high potency suites.
Converting two non-potent rooms into a state-of-the-art space that safely handles products up to PBLEC 4 has allowed teams at our Philadelphia Chelsea Parkway facility to increase efficiency and ability to manage more potent materials.
The newly designed spaces include dedicated airlocks, showers, and cleaning rooms for handling HPAPI products to greater reduce risk of cross-contamination between suites. This allows for a more streamlined workflow, as dispensing operations and processing can occur in well-defined spaces, giving greater attention to safety and ensuring product quality.
The enhancements better position our Chelsea Parkway facility to accommodate a range of PBLEC 5 products when new isolator equipment will be installed later this year.
“Enhancements made to our Chelsea Parkway facility reflect our dedication to safety in high potency handling and making improvements to ensure that we remain a drug product manufacturing partner of choice for our pharma clients.” said Marlene Leuenberger, Vice President and General Manager of Quotient Sciences’ Philadelphia facilities.
Our ability to process potent APIs and share fewer common spaces with non-potent areas significantly lowers the risk of operational disruptions. Reconfiguring these spaces has allowed for a 20% increase in capacity for HPAPI handling at the facility.
The facility recently completed a successful inspection by the Chinese National Medical Products Administration (NMPA) in December 2024. It also has been recently inspected by agencies including the U.S. FDA, Japanese Pharmaceuticals and Medical Devices Agency (PMDA), Brazilian Health Regulatory Agency (ANVISA), and Russian Ministry of Industry and Trade.
“We are dedicated to advancing our capabilities in the pharmaceutical manufacturing sector, particularly in high potency handling to greater meet the needs of clients working on oncology, orphan drugs for rare diseases, and other areas.” continued Ms. Leuenberger. “Recent improvements to operations at Chelsea Parkway allow us to better serve our clients while ensuring the highest standards of safety and compliance.”
Quotient Sciences remains an innovator in drug product development and manufacturing. For more information about our drug product capabilities, which include commercial drug product manufacturing, visit our Drug Product web page.
Get more details about our Boothwyn, Pa. (Chelsea Parkway) drug product manufacturing facility.
